He Hao Jie

1),,,. B [J]., 2017, 17(2):151-154. 2),,,. B [J]., 2016, 16(12):1085-1088. 3),. [J]., 2016, 32(5):323-324. 4),,,,. [J].,2018,35(08):52-53. 5),. 32 5 [J]., 2016, 32(5):333-333. 6),,. 32+4, 4 [J]., 2016, 32(5):334-335. 7),,., 2 [J]., 2015, 31(9):653-655. 8),. 31 9 [J]., 2015, 31(9):655-655. 9),,,. [J]., 2007, 42(8):515-517. 10),,,. 21 [J]., 2007, 16(4):250-254. 11),,,. [J]., 2006, 15(7):545-546. 12),. [J]., 2006, 26(12):1302-1307. 13),,,. [J]., 2004, 4(4):609-614. 14) Chen M, Huang H, He H, et al. Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines[J]. Cancer Science, 2015, 106(8):1075-83. 15) Dai Z, Yin J, He H, et al. Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines.[J]. Proteomics, 2010, 10(21):3789-99.